Contenido principal del artículo

JJ ELIZONDO ARMENDÁRIZ
Sección de Farmacia y Dietética. Clínica de Rehabilitación de Salud Mental. Avenida de Villava 53, 31015 Pamplona (Navarra)
España
Vol. 49 Núm. 2 (2008), Artículos Originales, Páginas 135-144
Recibido: jun 14, 2016 Publicado: jun 20, 2008
Derechos de autor Cómo citar

Resumen

Clozapina fue desarrollado como el primer fármaco antipsicótico atípico con actividad frente a los síntomas tantopositivos como negativos de la esquizofrenia. Tras su retirada temporal debido a la aparición de algunos casos deagranulocitosis, fue reintroducido en el mercado (en España en 1993) en respuesta a la necesidad de disponer deuna alternativa para los casos de esquizofrenia resistente al tratamiento. Los resultados de los estudios ponen demanifi esto que clozapina representa el “gold standard” actualmente para el tratamiento de la esquizofrenia resistentey en los desórdenes psicóticos severos. El bajo riesgo de agranulocitosis y muerte que conlleva el uso de clozapina,siempre que se realice dentro de un programa de vigilancia, es compensado por los benefi cios clínicos del fármacoen el tratamiento de la esquizofrenia y de otros desórdenes neurológicos.

Descargas

La descarga de datos todavía no está disponible.

Detalles del artículo

Citas

Bobon DP, Janssen PAJ, Bobon D, eds. The Neuroleptics: Modern Problems of Pharmacopsychiatry, vol.5; Basel, Switzerland: Karger, 1970

Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmacologischen und klinischen Befunden mit Clozapin). Pharmakopsychiatrie 1971; 4: 182-191

Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56: 241-248

Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group. Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796

Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V et al. The risks and benefit of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377-384

Cervera S, Seva A. Esquizofrenia resistente al tratamiento farmacológico. Actas Españolas de Psiquiatria 2006; 34 (1): 48-54

Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int J Clin Psychopharmacol 1996 ; 11 (suppl. 2): 67-71

Juárez-Reyes MG, Shumway M, Battle C, Bachetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995; 46: 801-806

Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549

Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry 1988; 145: 684-689

Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcomes in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-983

Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patient with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526.

Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risk and mortality: result of a 10-year naturalistic study. J Clin Psychiatry 2005; 66: 1116-1121

Buckley P, Bartell J, Donenbirth K, Lee S; Toriqoe F, Schultz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23: 607-611

Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190

Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677

Pickard D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345-353

Lindenmayer JP; Grochowsky S, Mabugat L. Clozapine effects on positive and negative symptoms: a six month trial in treatment-refractory schizophrenia. J Clin Psychopharmacol 1994; 14: 201-204

Hagger C, Buckley P, Kenny JT, Friedman L, Ubogv D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-712

McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999; 60 (suppl. 12): 24-29

Ranjan R, Meltzer HY. Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253-258

Naber D. Optimizing Clozapine Treatment. J Clin Psychiatry 1999; 60 (suppl. 12): 35-38

Tiihönen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalizacion due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, doi:10-1136/bmj.38881.382755.2F (published 6 July 2006)

Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced-agranulocytosis: incidence and risk factor in the United States. N Eng J Med 1993; 329: 162-167

Lambertenghi Deliliers G. Blood dyscrasias in clozapina-treated patients in Italy. Haematologica 2000; 85(3): 233-237

Alphs LD, Anand R. Clozapine : The Commitment to Patient Safety. J Clin Psychiatry 1999; 60 (suppl. 12): 39-42

Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005; 60: 759-764

Santamaría Ruiz B. Programa de seguimiento de clozapina; Madrid:Tesis doctoral, 1999

Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 1992; 160 (suppl. 17): 54-59.